Wells Fargo & Company Acadia Pharmaceuticals Inc Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Wells Fargo & Company holds 202,349 shares of ACAD stock, worth $4.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

202,349

Previous 187,902 7.69%

Holding current value

$4.06 Million

Previous $2.89 Million 28.43%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$14.29 - $18.76 $206,447 - $271,025	14,447 Added 7.69%	202,349 $3.71 Million
Q3 2024 Nov 13, 2024	BUY	$15.14 - $19.14 $33,080 - $41,820	2,185 Added 1.18%	187,902 $2.89 Million
Q2 2024 Aug 13, 2024	BUY	$14.62 - $18.42 $1.23 Million - $1.54 Million	83,797 Added 82.22%	185,717 $3.02 Million
Q1 2024 May 10, 2024	BUY	$17.79 - $30.86 $244,096 - $423,430	13,721 Added 15.56%	101,920 $1.88 Million
Q4 2023 Feb 09, 2024	SELL	$20.78 - $31.77 $1.16 Million - $1.78 Million	-55,921 Reduced 38.8%	88,199 $2.76 Million
Q3 2023 Nov 13, 2023	SELL	$20.84 - $33.47 $892,723 - $1.43 Million	-42,837 Reduced 22.91%	144,120 $3 Million
Q2 2023 Aug 15, 2023	BUY	$17.8 - $25.65 $137,594 - $198,274	7,730 Added 4.31%	186,957 $4.48 Million
Q1 2023 May 12, 2023	BUY	$16.32 - $20.92 $1.28 Million - $1.64 Million	78,190 Added 77.39%	179,227 $3.37 Million
Q4 2022 Feb 13, 2023	SELL	$14.2 - $18.63 $30,728 - $40,315	-2,164 Reduced 2.1%	101,037 $1.61 Million
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $8,254 - $10,687	-585 Reduced 0.56%	103,201 $1.69 Million
Q2 2022 Aug 12, 2022	SELL	$13.01 - $27.22 $803,458 - $1.68 Million	-61,757 Reduced 37.31%	103,786 $1.46 Million
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $814,880 - $1.07 Million	-38,915 Reduced 19.03%	165,543 $4.01 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $138,870 - $224,061	8,271 Added 4.22%	204,458 $4.77 Million
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $596,420 - $936,206	37,796 Added 23.86%	196,187 $3.26 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $69,607 - $98,382	3,588 Added 2.32%	158,391 $3.86 Million
Q1 2021 May 13, 2021	SELL	$25.02 - $54.99 $556,544 - $1.22 Million	-22,244 Reduced 12.56%	154,803 $3.99 Million
Q4 2020 Feb 09, 2021	SELL	$41.04 - $56.79 $1 Million - $1.39 Million	-24,481 Reduced 12.15%	177,047 $9.47 Million
Q3 2020 Nov 05, 2020	SELL	$36.42 - $57.0 $592,662 - $927,561	-16,273 Reduced 7.47%	201,528 $8.31 Million
Q2 2020 Aug 13, 2020	SELL	$39.26 - $52.73 $481,327 - $646,469	-12,260 Reduced 5.33%	217,801 $10.6 Million
Q1 2020 May 14, 2020	BUY	$31.65 - $46.87 $7.28 Million - $10.8 Million	230,061 New	230,061 $9.72 Million

Others Institutions Holding ACAD

# of Institutions

306

Shares Held

157M

Call Options Held

828K

Put Options Held

317K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.24B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Acadia Pharmaceuticals Inc Transaction History